Jennison Associates LLC boosted its position in Juno Therapeutics, Inc. (NASDAQ:JUNO) by 162.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,988,708 shares of the biopharmaceutical company’s stock after acquiring an additional 1,229,622 shares during the period. Jennison Associates LLC owned 1.74% of Juno Therapeutics worth $89,213,000 as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. The Manufacturers Life Insurance Company lifted its holdings in shares of Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 228 shares in the last quarter. Pacad Investment Ltd. bought a new position in shares of Juno Therapeutics in the second quarter valued at approximately $105,000. QS Investors LLC bought a new position in shares of Juno Therapeutics in the second quarter valued at approximately $135,000. Macquarie Group Ltd. bought a new position in shares of Juno Therapeutics in the second quarter valued at approximately $248,000. Finally, Leisure Capital Management bought a new position in shares of Juno Therapeutics in the second quarter valued at approximately $255,000. Institutional investors and hedge funds own 66.71% of the company’s stock.
A number of research analysts have recently weighed in on JUNO shares. Wedbush upgraded Juno Therapeutics from a “neutral” rating to an “outperform” rating and set a $42.00 target price on the stock in a report on Tuesday, August 29th. Wells Fargo & Company restated an “outperform” rating and issued a $54.00 target price (up previously from $35.00) on shares of Juno Therapeutics in a report on Tuesday, September 5th. Raymond James Financial, Inc. raised their target price on Juno Therapeutics from $45.00 to $61.00 and gave the company an “outperform” rating in a report on Friday, November 3rd. Standpoint Research reaffirmed a “reduce” rating on shares of Juno Therapeutics in a research report on Thursday, August 31st. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $44.00 price target on shares of Juno Therapeutics in a research report on Friday, October 6th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $44.20.
In other news, insider Sunil Agarwal sold 7,285 shares of Juno Therapeutics stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $44.76, for a total value of $326,076.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Robert Azelby sold 12,869 shares of Juno Therapeutics stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $39.95, for a total value of $514,116.55. Following the completion of the transaction, the executive vice president now owns 50,289 shares of the company’s stock, valued at $2,009,045.55. The disclosure for this sale can be found here. Over the last quarter, insiders sold 79,670 shares of company stock valued at $3,553,777. 15.26% of the stock is owned by company insiders.
Juno Therapeutics, Inc. (JUNO) traded up $3.16 during trading hours on Monday, reaching $57.59. The company’s stock had a trading volume of 2,085,500 shares, compared to its average volume of 2,067,684. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77. Juno Therapeutics, Inc. has a twelve month low of $17.52 and a twelve month high of $61.59.
Juno Therapeutics (NASDAQ:JUNO) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.07. The business had revenue of $44.80 million during the quarter, compared to the consensus estimate of $18.12 million. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The business’s revenue for the quarter was up 115.4% on a year-over-year basis. During the same period last year, the business posted ($0.57) earnings per share. equities research analysts predict that Juno Therapeutics, Inc. will post -4.02 EPS for the current fiscal year.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.